Covid19
Conditions
Brief summary
The use of growth hormone in obese cases with COVID-19 may help them to recover earlier.
Detailed description
It is well known that lymphoid organs such the thymus, the spleen and peripheral blood produce growth hormone (GH) and GH receptor is expressed on different subpopulations of lymphocytes. Many in vitro and in animal studies demonstrate an important role of GH in immunoregulation. GH stimulates T and B cells proliferation and immunoglobulin synthesis, enhances the maturation of myeloid progenitor cells and is also able to modulate cytokine response. The use of growth hormone in obese cases with COVID-19 may help them to recover earlier.
Interventions
DRUGGrowth Hormone
Recombinant growth hormone will be used
DRUGPlacebo
Saline injection with the same amount
Sponsors
ClinAmygate
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Obese with BMI \> 30
Exclusion criteria
* History of hypersensitivity to GH
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Need for hospitalization | one to two weeks | need to be hospitalized due to deterioration |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time to recovery | one to four weeks | Time to recovery from symptoms and signs |
| Percentage of reduction in CRP | one to two weeks | Percentage of reduction in CRP |
| Percentage of reduction in LDH | one to two weeks | Percentage of reduction in LDH |
| Percentage of reduction in Ferritin | one to two weeks | Percentage of reduction in Ferritin |
| Time to recovery from leucopenia | one to two weeks | Time to recovery from leucopenia |
Countries
Egypt
Outcome results
None listed